Alterity Therapeutics Limited's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Alterity Therapeutics Limited's ROA in the fourth quarter of 2025?
Alterity Therapeutics Limited recorded a cumulative net loss of $-12 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -22.41%.

However, within the Healthcare sector 423 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4654.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) IV. Quarter
Y / Y Total Assets Change	40.96 %	40.96 %	63.72 %	139.42 %	-5.96 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-19	-19	-19	-19
Return On Assets (TTM)	-22.41 %	-38.53 %	-42.45 %	-46.99 %	-56.25 %
ATHE's Total Ranking	# 4654	#	#	#	#
Total Assets (TTM) in million	63	63	45	46	45
Seq. Total Assets Change	0 %	40.96 %	-2.83 %	2.91 %	0 %
Seq. Net Income Change	-	-	-	-	-

ATHE's 5 Years Annual ROA >> Back to ATHE Management Effectiveness >> Compare ATHE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 158
Sector	# 424
Overall	# 3783

Return On Assets Statistics
High	Average	Low
-26.39 %	-66.57 %	-132.23 %
(Jun 30 2025)		(Jun 30 2020)

Financial Statements
Alterity Therapeutics Limited's Assets	$ 63 million	ATHE's Balance sheet
Alterity Therapeutics Limited's Income	$ -12 million	Quarterly ATHE's Income Statement
ATHE's Income by Division		See ATHE's Income by Division

Annual Return On Assets	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	139.42 %	-29.63 %	-52.08 %	1.67 %	62.57 %
Total Assets in million	46	19	27	57	56
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-12	-19	0	-9	-11
Annual Return On Assets	-26.39 %	-99.48 %	0 %	-16.35 %	-20.4 %

ATHE's 5 Years Annual ROA >> Back to ATHE Management Effectiveness >> Compare ATHE ROA to its Competitors

More Return On Assets Ratios
ATHE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ATHE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ATHE's Competitors
Subscribers only: Roa for Alterity Therapeutics Limited's Suppliers
Subscribers only: Return On Assets for ATHE's Customers

You may also want to know
ATHE's Roi	ATHE's Inventory Turnover Ratio	ATHE's Growth Rates	ATHE's Dividend Comparisons
	ATHE's Profitability Ratios	ATHE's Asset Turnover Ratio	ATHE's Dividend Growth
ATHE's Roe	ATHE's Valuation Ratios	ATHE's Financial Strength Ratios	ATHE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-10T01:49:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.